Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells

Current Medicinal Chemistry

Volumn 18, Issue 18, 2011, Pages 2715-2726

  Martelli, A M ^a,b   Evangelisti, C ^a   Follo, M Y ^a   Ramazzotti, G ^a   Fini, M ^c   Giardino, R ^c   Manzoli, L ^a   McCubrey, J A ^d   Cocco, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CNR   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cancer stem cells; Differentiation; Leukemic stem cells; PI3K Akt mTOR; Proliferation; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; AP 23753; CCI 7709; DASATINIB; ETOPOSIDE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TRICIRIBINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN TARGETING; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; MAMMALS; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79959353534     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796011201     Document Type: Article

References (178)

1. Polyak, K.; Hahn, W. C., Roots and stems: stem cells in cancer. Nat. Med., 2006, 12, 296-300. (Pubitemid 43355075)
2. Lage, H., An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci., 2008, 65, 3145-3167.
3. Korkaya, H.; Wicha, M. S., Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs, 2007, 21, 299-310. (Pubitemid 47529469)
4. Saito, Y.; Uchida, N.; Tanaka, S.; Suzuki, N.; Tomizawa-Murasawa, M.; Sone, A.; Najima, Y.; Takagi, S.; Aoki, Y.; Wake, A.; Taniguchi, S.; Shultz, L. D.; Ishikawa, F., Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol., 2010, 28, 275-280.
5. Misaghian, N.; Ligresti, G.; Steelman, L. S.; Bertrand, F. E.; Basecke, J.; Libra, M.; Nicoletti, F.; Stivala, F.; Milella, M.; Tafuri, A.; Cervello, M.; Martelli, A. M.; McCubrey, J. A., Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 2009, 23, 25-42.
6. Yuan, T. L.; Cantley, L. C., PI3K pathway alterations in cancer: variations on a theme. Oncogene, 2008, 27, 5497-5510.
7. Engelman, J. A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer, 2009, 9, 550-562.
8. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Cancer, 2009, 8, 627-644.
9. Campbell, L. L.; Polyak, K., Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle, 2007, 6, 2332-2338. (Pubitemid 350058682)
10. Dick, J. E., Stem cells: Self-renewal writ in blood. Nature, 2003, 423, 231-233. (Pubitemid 40852681)
11. Dick, J. E., Breast cancer stem cells revealed. Proc. Natl. Acad. Sci. USA, 2003, 100, 3547-3549. (Pubitemid 36418067)
12. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L., Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111. (Pubitemid 33041634)
13. Sullivan, J. P.; Minna, J. D.; Shay, J. W., Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev., 2010, 29, 61-72.
14. Chiu, P. P.; Jiang, H.; Dick, J. E., Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood, 2010, 116, 5268-5279.
15. Sehl, M. E.; Sinsheimer, J. S.; Zhou, H.; Lange, K. L., Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res., 2009, 69, 9481-9489.
16. Dick, J. E., Stem cell concepts renew cancer research. Blood, 2008, 112, 4793-4807.
17. Visvader, J. E.; Lindeman, G. J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer, 2008, 8, 755-768.
18. Rosen, J. M.; Jordan, C. T., The increasing complexity of the cancer stem cell paradigm. Science, 2009, 324, 1670-1673.
19. Gilliland, D. G.; Griffin, J. D., The roles of FLT3 in hematopoiesis and leukemia. Blood, 2002, 100, 1532-1542. (Pubitemid 34925124)
20. Hermann, P. C.; Huber, S. L.; Herrler, T.; Aicher, A.; Ellwart, J. W.; Guba, M.; Bruns, C. J.; Heeschen, C., Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007, 1, 313-323. (Pubitemid 47355323)
21. Barabe, F.; Kennedy, J. A.; Hope, K. J.; Dick, J. E., Modeling the initiation and progression of human acute leukemia in mice. Science, 2007, 316, 600-604. (Pubitemid 46683146)
22. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; Sawyers, C. L., Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002, 2, 117-125. (Pubitemid 41039112)
23. Lemoli, R. M.; Salvestrini, V.; Bianchi, E.; Bertolini, F.; Fogli, M.; Amabile, M.; Tafuri, A.; Salati, S.; Zini, R.; Testoni, N.; Rabascio, C.; Rossi, L.; Martin-Padura, I.; Castagnetti, F.; Marighetti, P.; Martinelli, G.; Baccarani, M.; Ferrari, S.; Manfredini, R., Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34-cell population with intrinsic resistance to imatinib. Blood, 2009, 114, 5191-5200.
24. Odoux, C.; Fohrer, H.; Hoppo, T.; Guzik, L.; Stolz, D. B.; Lewis, D. W.; Gollin, S. M.; Gamblin, T. C.; Geller, D. A.; Lagasse, E., A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res., 2008, 68, 6932-6941.
25. Takebe, N.; Ivy, S. P., Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways. Clin. Cancer Res., 2010, 16, 3106-3112.
26. Jamieson, C. H.; Ailles, L. E.; Dylla, S. J.; Muijtjens, M.; Jones, C.; Zehnder, J. L.; Gotlib, J.; Li, K.; Manz, M. G.; Keating, A.; Sawyers, C. L.; Weissman, I. L., Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med., 2004, 351, 657-667. (Pubitemid 39063268)
27. Guibal, F. C.; Alberich-Jorda, M.; Hirai, H.; Ebralidze, A.; Levantini, E.; Di Ruscio, A.; Zhang, P.; Santana-Lemos, B. A.; Neuberg, D.; Wagers, A. J.; Rego, E. M.; Tenen, D. G., Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood, 2009, 114, 5415-5425.
28. Zhou, B. B.; Zhang, H.; Damelin, M.; Geles, K. G.; Grindley, J. C.; Dirks, P. B., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Cancer, 2009, 8, 806-823.
29. Kelly, P. N.; Dakic, A.; Adams, J. M.; Nutt, S. L.; Strasser, A., Tumor growth need not be driven by rare cancer stem cells. Science, 2007, 317, 337. (Pubitemid 47106366)
30. Hope, K. J.; Jin, L.; Dick, J. E., Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Na.t Immunol, 2004, 5, 738-743. (Pubitemid 39023306)
31. Jin, L.; Lee, E. M.; Ramshaw, H. S.; Busfield, S. J.; Peoppl, A. G.; Wilkinson, L.; Guthridge, M. A.; Thomas, D.; Barry, E. F.; Boyd, A.; Gearing, D. P.; Vairo, G.; Lopez, A. F.; Dick, J. E.; Lock, R. B., Monoclonal antibodymediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 2009, 5, 31-42.
32. Quintana, E.; Shackleton, M.; Sabel, M. S.; Fullen, D. R.; Johnson, T. M.; Morrison, S. J., Efficient tumour formation by single human melanoma cells. Nature, 2008, 456, 593-598.
33. Labarge, M. A., The Difficulty of Targeting Cancer Stem Cell Niches. Clin. Cancer Res., 2010, 16, 3121-3129.
34. Bonnet, D.; Bhatia, M.; Wang, J. C.; Kapp, U.; Dick, J. E., Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant, 1999, 23, 203-209. (Pubitemid 29078332)
35. Hill, R. P.; Milas, L., The proportion of stem cells in murine tumors. Int. J. Radiat. Oncol Biol Phys., 1989, 16, 513-518. (Pubitemid 19077222)
36. Bonnet, D.; Dick, J. E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3, 730-737. (Pubitemid 27298715)
37. Taussig, D. C.; Miraki-Moud, F.; Anjos-Afonso, F.; Pearce, D. J.; Allen, K.; Ridler, C.; Lillington, D.; Oakervee, H.; Cavenagh, J.; Agrawal, S. G.; Lister, T. A.; Gribben, J. G.; Bonnet, D., Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood, 2008, 112, 568-575.
38. Abrahamsson, A. E.; Geron, I.; Gotlib, J.; Dao, K. H.; Barroga, C. F.; Newton, I. G.; Giles, F. J.; Durocher, J.; Creusot, R. S.; Karimi, M.; Jones, C.; Zehnder, J. L.; Keating, A.; Negrin, R. S.; Weissman, I. L.; Jamieson, C. H., Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation. Proc. Natl Acad. Sci. USA, 2009, 106, 3925-3929.
39. Cox, C. V.; Martin, H. M.; Kearns, P. R.; Virgo, P.; Evely, R. S.; Blair, A., Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood, 2007, 109, 674-682. (Pubitemid 46105969)
40. Park, S. Y.; Lee, H. E.; Li, H.; Shipitsin, M.; Gelman, R.; Polyak, K., Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res., 2010, 16, 876-887.
41. Eaton, C. L.; Colombel, M.; van der Pluijm, G.; Cecchini, M.; Wetterwald, A.; Lippitt, J.; Rehman, I.; Hamdy, F.; Thalman, G., Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate, 2010, 70, 875-882.
42. Li, C.; Heidt, D. G.; Dalerba, P.; Burant, C. F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M. F.; Simeone, D. M., Identification of pancreatic cancer stem cells. Cancer Res., 2007, 67, 1030-1037.
43. Sikandar, S. S.; Pate, K. T.; Anderson, S.; Dizon, D.; Edwards, R. A.; Waterman, M. L.; Lipkin, S. M., NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res., 2010, 70, 1469-1478.
44. Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; Di Virgilio, A.; Conticello, C.; Ruco, L.; Peschle, C.; De Maria, R., Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ, 2008, 15, 504-514. (Pubitemid 351267301)
45. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B., Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401. (Pubitemid 39551674)
46. Yamashita, T.; Honda, M.; Nio, K.; Nakamoto, Y.; Takamura, H.; Tani, T.; Zen, Y.; Kaneko, S., Oncostatin m renders epithelial cell adhesion moleculepositive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res., 2010, 70, 4687-4697.
47. Goodell, M. A.; Brose, K.; Paradis, G.; Conner, A. S.; Mulligan, R. C., Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med, 1996, 183, 1797-1806. (Pubitemid 26134320)
48. Goodell, M. A.; Rosenzweig, M.; Kim, H.; Marks, D. F.; DeMaria, M.; Paradis, G.; Grupp, S. A.; Sieff, C. A.; Mulligan, R. C.; Johnson, R. P, Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med, 1997, 3, 1337-1345. (Pubitemid 28011033)
49. Yamazaki, J.; Mizukami, T.; Takizawa, K.; Kuramitsu, M.; Momose, H.; Masumi, A.; Ami, Y.; Hasegawa, H.; Hall, W. W.; Tsujimoto, H.; Hamaguchi, I.; Yamaguchi, K., Identification of cancer stem cells in a Taxtransgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood, 2009, 114, 2709-2720.
50. Moshaver, B.; van Rhenen, A.; Kelder, A.; van der Pol, M.; Terwijn, M.; Bachas, C.; Westra, A. H.; Ossenkoppele, G. J.; Zweegman, S.; Schuurhuis, G. J., Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells, 2008, 26, 3059-3067.
51. Salcido, C. D.; Larochelle, A.; Taylor, B. J.; Dunbar, C. E.; Varticovski, L., Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br. J. Cancer, 2010, 102, 1636-1644.
52. Mimeault, M.; Johansson, S. L.; Henichart, J. P.; Depreux, P.; Batra, S. K., Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol. Cancer Ther., 2010, 9, 617-630.
53. Nakanishi, T.; Chumsri, S.; Khakpour, N.; Brodie, A. H.; Leyland-Jones, B.; Hamburger, A. W.; Ross, D. D.; Burger, A. M., Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br. J. Cancer, 2010, 102, 815-826.
54. Harris, M. A.; Yang, H.; Low, B. E.; Mukherjee, J.; Guha, A.; Bronson, R. T.; Shultz, L. D.; Israel, M. A.; Yun, K., Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res., 2008, 68, 10051-10059.
55. Chiba, T.; Miyagi, S.; Saraya, A.; Aoki, R.; Seki, A.; Morita, Y.; Yonemitsu, Y.; Yokosuka, O.; Taniguchi, H.; Nakauchi, H.; Iwama, A., The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res., 2008, 68, 7742-7749.
56. Chiba, T.; Kita, K.; Zheng, Y. W.; Yokosuka, O.; Saisho, H.; Iwama, A.; Nakauchi, H.; Taniguchi, H., Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 2006, 44, 240-251. (Pubitemid 44049156)
57. Franke, T. F., PI3K/Akt: getting it right matters. Oncogene, 2008, 27, 6473-6488.
58. Jia, S.; Roberts, T. M.; Zhao, J. J., Should individual PI3 kinase isoforms be targeted in cancer? Curr. Opin. Cell Biol., 2009, 21, 199-208.
59. Fruman, D. A.; Bismuth, G., Fine tuning the immune response with PI3K. Immunol. Rev., 2009, 228, 253-272.
60. Kok, K.; Geering, B.; Vanhaesebroeck, B., Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci., 2009, 34, 115-127.
61. Falasca, M.; Maffucci, T., Rethinking phosphatidylinositol 3-monophosphate. Biochim. Biophys. Acta, 2009, 1793, 1795-1803.
62. Backer, J. M., The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem. J., 2008, 410, 1-17. (Pubitemid 351300321)
63. Morselli, E.; Galluzzi, L.; Kepp, O.; Vicencio, J. M.; Criollo, A.; Maiuri, M. C.; Kroemer, G., Anti-and pro-tumor functions of autophagy. Biochim. Biophys. Acta, 2009, 1793, 1524-1532.
64. Brazil, D. P.; Yang, Z. Z.; Hemmings, B. A., Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci., 2004, 29, 233-242. (Pubitemid 38591317)
65. Chin, Y. R.; Toker, A., Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell. Signal., 2009, 21, 470-476.
66. Martelli, A. M.; Nyakern, M.; Tabellini, G.; Bortul, R.; Tazzari, P. L.; Evangelisti, C.; Cocco, L., Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia, 2006, 20, 911-928. (Pubitemid 43797279)
67. Downward, J., PI 3-kinase, Akt and cell survival. Semin. Cell Devel. Biol., 2004, 15, 177-182. (Pubitemid 38251646)
68. Pearce, L. R.; Komander, D.; Alessi, D. R., The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol., 2010, 11, 9-22.
69. Memmott, R. M.; Dennis, P. A., Akt-dependent and-independent mechanisms of mTOR regulation in cancer. Cell. Signal., 2009, 21, 656-664.
70. Dowling, R. J.; Topisirovic, I.; Fonseca, B. D.; Sonenberg, N., Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta, 2010, 1804, (3), 433-439.
71. Jiang, B. H.; Liu, L. Z., Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat., 2008, 11, 63-76.
72. Kim, D. H.; Sarbassov, D. D.; Ali, S. M.; King, J. E.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M., mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 2002, 110, 163-175. (Pubitemid 34876545)
73. Oshiro, N.; Yoshino, K.; Hidayat, S.; Tokunaga, C.; Hara, K.; Eguchi, S.; Avruch, J.; Yonezawa, K., Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells, 2004, 9, 359-366. (Pubitemid 38514871)
74. Shor, B.; Gibbons, J. J.; Abraham, R. T.; Yu, K., Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle, 2009, 8, 3831-3837.
75. Garcia-Echeverria, C., Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. Med. Chem. Lett., 2010, 20, 4308-4312.
76. Dunlop, E. A.; Tee, A. R., Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell. Signal., 2009, 21, 827-835.
77. Rosner, M.; Hengstschlager, M., Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum. Mol. Genet., 2008, 17, 2934-2948.
78. Tamburini, J.; Green, A. S.; Chapuis, N.; Bardet, V.; Lacombe, C.; Mayeux, P.; Bouscary, D., Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle, 2009, 8, 3893-3899.
79. Browne, G. J.; Proud, C. G., A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol. Cell Biol., 2004, 24, 2986-2997. (Pubitemid 38381287)
80. Ma, X. M.; Blenis, J., Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol, 2009, 10, 307-318.
81. Mamane, Y.; Petroulakis, E.; LeBacquer, O.; Sonenberg, N., mTOR, translation initiation and cancer. Oncogene, 2006, 25, 6416-6422. (Pubitemid 44582285)
82. Laplante, M.; Sabatini, D. M., mTOR signaling at a glance. J. Cell Sci, 2009, 122, 3589-3594.
83. Schieke, S. M.; Phillips, D.; McCoy, J. P., Jr.; Aponte, A. M.; Shen, R. F.; Balaban, R. S.; Finkel, T., The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem., 2006, 281, 27643-27652. (Pubitemid 44401789)
84. Cunningham, J. T.; Rodgers, J. T.; Arlow, D. H.; Vazquez, F.; Mootha, V. K.; Puigserver, P., mTOR controls mitochondrial oxidative function through a YY1-PGC-1α transcriptional complex. Nature, 2007, 450, 736-740. (Pubitemid 350207689)
85. Jung, C. H.; Ro, S. H.; Cao, J.; Otto, N. M.; Kim, D. H., mTOR regulation of autophagy FEBS Lett, 2010, 584, 1287-1295.
86. Eskelinen, E. L.; Saftig, P., Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta, 2009, 1793, 664-673.
87. Mavrakis, K. J.; Zhu, H.; Silva, R. L.; Mills, J. R.; Teruya-Feldstein, J.; Lowe, S. W.; Tam, W.; Pelletier, J.; Wendel, H. G., Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev., 2008, 22, 2178-2188.
88. Wang, L.; Harris, T. E.; Lawrence, J. C., Jr., Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J. Biol. Chem., 2008, 283, 15619-15627.
89. Fonseca, B. D.; Smith, E. M.; Lee, V. H.; MacKintosh, C.; Proud, C. G., PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem., 2007, 282, 24514-24524. (Pubitemid 47347551)
90. Ma, L.; Chen, Z.; Erdjument-Bromage, H.; Tempst, P.; Pandolfi, P. P., Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell, 2005, 121, 179-193. (Pubitemid 40546387)
91. Jin, T.; George Fantus, I.; Sun, J., Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of β-catenin. Cell. Signal, 2008, 20, 1697-1704.
92. Inoki, K.; Ouyang, H.; Zhu, T.; Lindvall, C.; Wang, Y.; Zhang, X.; Yang, Q.; Bennett, C.; Harada, Y.; Stankunas, K.; Wang, C. Y.; He, X.; MacDougald, O. A.; You, M.; Williams, B. O.; Guan, K. L., TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 2006, 126, 955-968. (Pubitemid 44310775)
93. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Lopez-Bonet, E.; Menendez, J. A., AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle, 2009, 8, 3679-3683.
94. Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; Turk, B. E.; Shaw, R. J., AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell, 2008, 30, 214-226. (Pubitemid 351626684)
95. Brugarolas, J.; Lei, K.; Hurley, R. L.; Manning, B. D.; Reiling, J. H.; Hafen, E.; Witters, L. A.; Ellisen, L. W.; Kaelin, W. G., Jr., Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev, 2004, 18, 2893-2904. (Pubitemid 39602308)
96. Reiling, J. H.; Hafen, E., The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev, 2004, 18, 2879-2892. (Pubitemid 39602307)
97. Sofer, A.; Lei, K.; Johannessen, C. M.; Ellisen, L. W., Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell Biol, 2005, 25, 5834-5845. (Pubitemid 40946541)
98. DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L. W., Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev, 2008, 22, 239-251.
99. Kim, E.; Goraksha-Hicks, P.; Li, L.; Neufeld, T. P.; Guan, K. L., Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol, 2008, 10, 935-945.
100. Sancak, Y.; Peterson, T. R.; Shaul, Y. D.; Lindquist, R. A.; Thoreen, C. C.; Bar-Peled, L.; Sabatini, D. M., The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science, 2008, 320, 1496-1501. (Pubitemid 351929429)
101. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098-1101. (Pubitemid 40262113)
102. Guertin, D. A.; Stevens, D. M.; Saitoh, M.; Kinkel, S.; Crosby, K.; Sheen, J. H.; Mullholland, D. J.; Magnuson, M. A.; Wu, H.; Sabatini, D. M., mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell, 2009, 15, 148-159.
103. Garcia-Martinez, J. M.; Alessi, D. R., mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J., 2008, 416, 375-385.
104. Kitowska, A.; Pawelczyk, T., N-myc downstream regulated 1 gene and its place in the cellular machinery. Acta Biochim. Pol, 2010, 57, 15-21.
105. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M. A.; Hall, A.; Hall, M. N., Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol, 2004, 6, 1122-1128. (Pubitemid 39468014)
106. Huang, J.; Zhang, Y.; Bersenev, A.; O'Brien, W. T.; Tong, W.; Emerson, S. G.; Klein, P. S., Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J. Clin. Invest., 2009, 119, 3519-3529.
107. Hernandez-Negrete, I.; Carretero-Ortega, J.; Rosenfeldt, H.; Hernandez-Garcia, R.; Calderon-Salinas, J. V.; Reyes-Cruz, G.; Gutkind, J. S.; Vazquez-Prado, J., P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J. Biol. Chem., 2007, 282, 23708-23715. (Pubitemid 47311970)
108. Sparks, C. A.; Guertin, D. A., Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene, 2010, 29, 3733-3744.
109. Huang, J.; Dibble, C. C.; Matsuzaki, M.; Manning, B. D., The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell Biol., 2008, 28, 4104-4115. (Pubitemid 351812994)
110. Shah, O. J.; Wang, Z.; Hunter, T., Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol., 2004, 14, 1650-1656. (Pubitemid 39239362)
111. Bhaskar, P. T.; Hay, N., The two TORCs and Akt. Dev. Cell, 2007, 12, 487-502. (Pubitemid 46523652)
112. Lang, S. A.; Hackl, C.; Moser, C.; Fichtner-Feigl, S.; Koehl, G. E.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O., Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim. Biophys. Acta, 2010, 1803, 435-442.
113. Xu, X.; Sarikas, A.; Dias-Santagata, D. C.; Dolios, G.; Lafontant, P. J.; Tsai, S. C.; Zhu, W.; Nakajima, H.; Nakajima, H. O.; Field, L. J.; Wang, R.; Pan, Z. Q., The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol. Cell, 2008, 30,.403-414. (Pubitemid 351672370)
114. Sriburi, R.; Jackowski, S.; Mori, K.; Brewer, J. W., XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J. Cell Biol., 2004, 167, 35-41. (Pubitemid 39363412)
115. Dibble, C. C.; Asara, J. M.; Manning, B. D., Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell Biol., 2009, 29, 5657-5670.
116. Boulbes, D.; Chen, C. H.; Shaikenov, T.; Agarwal, N. K.; Peterson, T. R.; Addona, T. A.; Keshishian, H.; Carr, S. A.; Magnuson, M. A.; Sabatini, D. M.; Sarbassov, D. D., Rictor Phosphorylation on the Thr-1135 Site Does Not Require Mammalian Target of Rapamycin Complex 2. Mol. Cancer Res., 2010, 8, 896-906.
117. Keniry, M.; Parsons, R., The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene, 2008, 27, 5477-5485.
118. Stiles, B. L., Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles. In. J. Biochem. Cell Biol., 2009, 41, 757-761.
119. Kalesnikoff, J.; Sly, L. M.; Hughes, M. R.; Buchse, T.; Rauh, M. J.; Cao, L. P.; Lam, V.; Mui, A.; Huber, M.; Krystal, G., The role of SHIP in cytokineinduced signaling. Rev. Physiol. Biochem. Pharmacol., 2003, 149, 87-103.
120. Bunney, T. D.; Katan, M., Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat. Rev. Cancer, 2010, 10, 342-352.
121. Eichhorn, P. J.; Creyghton, M. P.; Bernards, R., Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta, 2009, 1795, 1-15.
122. Brognard, J.; Newton, A. C., PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol. Metab., 2008, 19, 223-230. (Pubitemid 351993013)
123. Hirano, I.; Nakamura, S.; Yokota, D.; Ono, T.; Shigeno, K.; Fujisawa, S.; Shinjo, K.; Ohnishi, K., Depletion of Pleckstrin homology domain leucinerich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms. J. Biol. Chem., 2009, 284, 22155-22165.
124. Lane, S. W.; Scadden, D. T.; Gilliland, D. G., The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood, 2009, 114, 1150-1157.
125. Zhang, J.; Grindley, J. C.; Yin, T.; Jayasinghe, S.; He, X. C.; Ross, J. T.; Haug, J. S.; Rupp, D.; Porter-Westpfahl, K. S.; Wiedemann, L. M.; Wu, H.; Li, L., PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature, 2006, 441, 518-522. (Pubitemid 44050154)
126. Yilmaz, O. H.; Valdez, R.; Theisen, B. K.; Guo, W.; Ferguson, D. O.; Wu, H.; Morrison, S. J., Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 2006, 441, 475-482. (Pubitemid 44050144)
127. Yu, H.; Li, Y.; Gao, C.; Fabien, L.; Jia, Y.; Lu, J.; Silberstein, L. E.; Pinkus, G. S.; Ye, K.; Chai, L.; Luo, H. R., Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. Leukemia, 2010, 24, 1077-1080.
128. Peng, C.; Chen, Y.; Yang, Z.; Zhang, H.; Osterby, L.; Rosmarin, A. G.; Li, S., PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood, 2010, 115, 626-635.
129. Bruns, I.; Czibere, A.; Fischer, J. C.; Roels, F.; Cadeddu, R. P.; Buest, S.; Bruennert, D.; Huenerlituerkoglu, A. N.; Stoecklein, N. H.; Singh, R.; Zerbini, L. F.; Jager, M.; Kobbe, G.; Gattermann, N.; Kronenwett, R.; Brors, B.; Haas, R., The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia, 2009, 23, 892-899.
130. Copland, M.; Hamilton, A.; Elrick, L. J.; Baird, J. W.; Allan, E. K.; Jordanides, N.; Barow, M.; Mountford, J. C.; Holyoake, T. L., Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 2006, 107, 4532-4539. (Pubitemid 43801382)
131. + CML cells. Blood, 2007, 109, 4016-4019. (Pubitemid 46641755)
132. Lakhanpal, G. K.; Vecchiarelli-Federico, L. M.; Li, Y. J.; Cui, J. W.; Bailey, M. L.; Spaner, D. E.; Dumont, D. J.; Barber, D. L.; Ben-David, Y., The inositol phosphatase SHIP-1 is negatively regulated by Fli-1 and its loss accelerates leukemogenesis. Blood, 2010, 116, 428-436.
133. Munugalavadla, V.; Sims, E. C.; Borneo, J.; Chan, R. J.; Kapur, R, Genetic and pharmacologic evidence implicating the p85α, but not p85p, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood, 2007, 110, 1612-1620. (Pubitemid 47443979)
134. Kharas, M. G.; Okabe, R.; Ganis, J. J.; Gozo, M.; Khandan, T.; Paktinat, M.; Gilliland, D. G.; Gritsman, K., Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood, 2010, 115, 1406-1415.
135. Muranyi, A. L.; Dedhar, S.; Hogge, D. E., Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk. Res., 2010, 34, 1358-1365.
136. Tabe, Y.; Jin, L.; Tsutsumi-Ishii, Y.; Xu, Y.; McQueen, T.; Priebe, W.; Mills, G. B.; Ohsaka, A.; Nagaoka, I.; Andreeff, M.; Konopleva, M., Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res., 2007, 67, 684-694. (Pubitemid 46192208)
137. Gan, B.; Sahin, E.; Jiang, S.; Sanchez-Aguilera, A.; Scott, K. L.; Chin, L.; Williams, D. A.; Kwiatkowski, D. J.; DePinho, R. A., mTORC1-dependent and-independent regulation of stem cell renewal, differentiation, and mobilization. Proc. Natl. Acad. Sci. USA, 2008, 105, 19384-19389.
138. Chen, C.; Liu, Y.; Liu, R.; Ikenoue, T.; Guan, K. L.; Liu, Y.; Zheng, P., TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J. Exp. Med, 2008, 205, 2397-2408.
139. Gan, B.; DePinho, R. A., mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle, 2009, 8, 1003-1006.
140. Xu, Q.; Thompson, J. E.; Carroll, M., mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood, 2005, 106, 4261-4268. (Pubitemid 41775935)
141. Tothova, Z.; Kollipara, R.; Huntly, B. J.; Lee, B. H.; Castrillon, D. H.; Cullen, D. E.; McDowell, E. P.; Lazo-Kallanian, S.; Williams, I. R.; Sears, C.; Armstrong, S. A.; Passegue, E.; DePinho, R. A.; Gilliland, D. G., FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell, 2007, 128, 325-339. (Pubitemid 46137992)
142. Naka, K.; Hoshii, T.; Muraguchi, T.; Tadokoro, Y.; Ooshio, T.; Kondo, Y.; Nakao, S.; Motoyama, N.; Hirao, A., TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature, 2010, 463, 676-680.
143. Zheng, H.; Ying, H.; Yan, H.; Kimmelman, A. C.; Hiller, D. J.; Chen, A. J.; Perry, S. R.; Tonon, G.; Chu, G. C.; Ding, Z.; Stommel, J. M.; Dunn, K. L.; Wiedemeyer, R.; You, M. J.; Brennan, C.; Wang, Y. A.; Ligon, K. L.; Wong, W. H.; Chin, L.; DePinho, R. A., p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 2008, 455, 1129-1133.
144. Rountree, C. B.; Ding, W.; He, L.; Stiles, B., Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells, 2009, 27, 290-299.
145. Korsten, H.; Ziel-van der Made, A.; Ma, X.; van der Kwast, T.; Trapman, J., Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS One, 2009, 4, e5662.
146. Dubrovska, A.; Kim, S.; Salamone, R. J.; Walker, J. R.; Maira, S. M.;
147. Yang, Y.; Iwanaga, K.; Raso, M. G.; Wislez, M.; Hanna, A. E.; Wieder, E. D.; Molldrem, J. J.; Wistuba, I. I.; Powis, G.; Demayo, F. J.; Kim, C. F.; Kurie, J. M., Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One, 2008, 3, e2220.
148. Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J. B.; Liotta, L. A.; Petricoin, E., 3rd; Zhang, Y, Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA, 2007, 104, 16158-16163. (Pubitemid 350099378)
149. Molina, J. R.; Hayashi, Y.; Stephens, C.; Georgescu, M. M., Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia, 2010, 12, 453-463.
150. Xin, L.; Lawson, D. A.; Witte, O. N., The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc. Natl. Acad. Sci. USA, 2005, 102, 6942-6947. (Pubitemid 40675421)
151. Lawson, D. A.; Zong, Y.; Memarzadeh, S.; Xin, L.; Huang, J.; Witte, O. N., Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl. Acad. Sci. USA, 2010, 107, 2610-2615.
152. Vermeulen, L.; Todaro, M.; De Sousa Mello, F.; Sprick, M. R.; Kemper, K.; Perez Alea, M.; Richel, D. J.; Stassi, G.; Medema, J. P, Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. USA, 2008, 105, 13427-13432.
153. Ricci-Vitiani, L.; Mollinari, C.; di Martino, S.; Biffoni, M.; Pilozzi, E.; Pagliuca, A.; Chiara de Stefano, M.; Circo, R.; Merlo, D.; De Maria, R.; Garaci, E., Thymosin p4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB J., 2010, 24, 4291-4301.
154. Iliopoulos, D.; Polytarchou, C.; Hatziapostolou, M.; Kottakis, F.; Maroulakou, I. G.; Struhl, K.; Tsichlis, P. N., MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Science Signal., 2009, 2, ra62.
155. LoPiccolo, J.; Blumenthal, G. M.; Bernstein, W. B.; Dennis, P. A., Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat., 2008, 11, 32-50.
156. Park, S.; Chapuis, N.; Bardet, V.; Tamburini, J.; Gallay, N.; Willems, L.; Knight, Z. A.; Shokat, K. M.; Azar, N.; Viguie, F.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D., PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 2008, 22, 1698-1706.
157. Berndt, N.; Yang, H.; Trinczek, B.; Betzi, S.; Zhang, Z.; Wu, B.; Lawrence, N. J.; Pellecchia, M.; Schonbrunn, E.; Cheng, J. Q.; Sebti, S. M., The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ., 2010, 17, 1795-1804.
158. Bhende, P. M.; Park, S. I.; Lim, M. S.; Dittmer, D. P.; Damania, B., The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia, 2010, 24, 1781-1784.
159. Evangelisti, C.; Ricci, F.; Tazzari, P. L.; Chiarini, F.; Battistelli, M.; Falcieri, E.; Ognibene, A.; Pagliaro, P.; Cocco, L.; McCubrey, J. A.; Martelli, A. M., Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J. Cell Physiol., 2011, 226, 822-831.
160. Chiarini, F.; Grimaldi, C.; Ricci, F.; Tazzari, P. L.; Evangelisti, C.; Ognibene, A.; Battistelli, M.; Falcieri, E.; Melchionda, F.; Pession, A.; Pagliaro, P.; McCubrey, J. A.; Martelli, A. M., Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. Cancer Res., 2010, 70, 8097-8107.
161. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008, 27, 1749-1758. (Pubitemid 351380265)
162. Mogi, M.; Yang, J.; Lambert, J. F.; Colvin, G. A.; Shiojima, I.; Skurk, C.; Summer, R.; Fine, A.; Quesenberry, P. J.; Walsh, K., Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J. Biol. Chem., 2003, 278, 39068-39075. (Pubitemid 37221810)
163. An, Y.; Ongkeko, W. M., ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin. Drug Metab. Toxicol., 2009, 5, 1529-1542.
164. Bram, E.; Ifergan, I.; Shafran, A.; Berman, B.; Jansen, G.; Assaraf, Y. G., Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother. Pharmacol., 2006, 58, 826-834. (Pubitemid 44351264)
165. Bleau, A. M.; Hambardzumyan, D.; Ozawa, T.; Fomchenko, E. I.; Huse, J. T.; Brennan, C. W.; Holland, E. C., PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell, 2009, 4, 226-235.
166. Hu, C.; Li, H.; Li, J.; Zhu, Z.; Yin, S.; Hao, X.; Yao, M.; Zheng, S.; Gu, J., Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis, 2008, 29, 2289-2297.
167. Kong, Q. L.; Hu, L. J.; Cao, J. Y.; Huang, Y. J.; Xu, L. H.; Liang, Y.; Xiong, D.; Guan, S.; Guo, B. H.; Mai, H. Q.; Chen, Q. Y.; Zhang, X.; Li, M. Z.; Shao, J. Y.; Qian, C. N.; Xia, Y. F.; Song, L. B.; Zeng, Y. X.; Zeng, M. S., Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog., 2010, 6, e1000940.
168. Gallia, G. L.; Tyler, B. M.; Hann, C. L.; Siu, I. M.; Giranda, V. L.; Vescovi, A. L.; Brem, H.; Riggins, G. J., Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol. Cancer Ther., 2009, 8, 386-393.
169. Hambardzumyan, D.; Becher, O. J.; Rosenblum, M. K.; Pandolfi, P. P.; Manova-Todorova, K.; Holland, E. C., PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev., 2008, 22, 436-448. (Pubitemid 351272752)
170. Martelli, A. M.; Evangelisti, C.; Chiarini, F.; Grimaldi, C.; Cappellini, A.; Ognibene, A.; McCubrey, J. A., The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim. Biophys. Acta, 2010, 1803, 991-1002.
171. Eyler, C. E.; Foo, W. C.; LaFiura, K. M.; McLendon, R. E.; Hjelmeland, A. B.; Rich, J. N., Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells, 2008, 26, 3027-3036.
172. Hambardzumyan, D.; Becher, O. J.; Holland, E. C., Cancer stem cells and survival pathways. Cell Cycle, 2008, 7, 1371-1378. (Pubitemid 351872575)
173. Pannuti, A.; Foreman, K.; Rizzo, P.; Osipo, C.; Golde, T.; Osborne, B.; Miele, L., Targeting Notch to Target Cancer Stem Cells. Clin. Cancer Res., 2010, 16, 3141-3152.
174. Merchant, A. A.; Matsui, W., Targeting Hedgehog - a Cancer Stem Cell Pathway. Clin. Cancer Res., 2010, 16, 3130-3140.
175. Mueller, M. T.; Hermann, P. C.; Witthauer, J.; Rubio-Viqueira, B.; Leicht, S. F.; Huber, S.; Ellwart, J. W.; Mustafa, M.; Bartenstein, P.; D'Haese, J. G.; Schoenberg, M. H.; Berger, F.; Jauch, K. W.; Hidalgo, M.; Heeschen, C., Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterolog y, 2009, 137, 1102-1113.
176. Riobo, N. A.; Lu, K.; Ai, X.; Haines, G. M.; Emerson, C. P., Jr., Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. USA, 2006, 103, 4505-4510.
177. Parathath, S. R.; Mainwaring, L. A.; Fernandez, L. A.; Campbell, D. O.; Kenney, A. M., Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors. Development, 2008, 135, 3291-3300.
178. Diamandis, M.; White, N. M.; Yousef, G. M., Personalized Medicine: Marking a New Epoch in Cancer Patient Management. Mol. Cancer Res., 2010, 8, 1175-1187.